An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) will host a conference call on May 6 at 4:30 p.m. ET to discuss its financial results for its fiscal second quarter ended March 31, 2024. Enanta is a clinical-stage biotechnology company focused on small molecule drugs for virology and immunology indications. The results will be reported after the U.S. market closes on May 6, 2024. The call will update on Enanta’s business, research, and development pipeline.
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) organizzerà una conferenza telefonica il 6 maggio alle 16:30 ET per discutere i risultati finanziari del suo secondo trimestre fiscale conclusosi il 31 marzo 2024. Enanta è un'azienda biotecnologica in fase clinica focalizzata su farmaci a piccole molecole per indicazioni di virologia e immunologia. I risultati saranno comunicati dopo la chiusura del mercato statunitense il 6 maggio 2024. Durante la chiamata verranno aggiornate le informazioni relative agli affari, alla ricerca e allo sviluppo di Enanta.
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) realizará una llamada de conferencia el 6 de mayo a las 4:30 p.m. ET para discutir sus resultados financieros del segundo trimestre fiscal, que finalizó el 31 de marzo de 2024. Enanta es una empresa biotecnológica en etapa clínica que se enfoca en medicamentos de pequeñas moléculas para virología e inmunología. Los resultados se informarán después del cierre del mercado estadounidense el 6 de mayo de 2024. La llamada proporcionará una actualización sobre los negocios de Enanta, la investigación y el desarrollo de su cartera.
에난타 파마슈티컬스, 인크.(NASDAQ: ENTA)는 2024년 3월 31일에 종료된 회계 년도 두 번째 분기의 재무 결과를 논의하기 위해 5월 6일 오후 4시 30분 ET에 컨퍼런스 콜을 개최할 예정입니다. 에난타는 바이러스학 및 면역학 적응증을 위한 소분자 약물에 중점을 둔 임상 단계의 생명공학 회사입니다. 결과는 2024년 5월 6일 미국 시장이 마감된 후 보고될 것입니다. 이 통화는 에난타의 사업, 연구 및 개발 파이프라인에 대한 업데이트를 제공할 것입니다.
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) organisera une conférence téléphonique le 6 mai à 16h30 ET pour discuter des résultats financiers de son deuxième trimestre fiscal se terminant le 31 mars 2024. Enanta est une entreprise de biotechnologie en phase clinique axée sur les médicaments à petites molécules pour les indications en virologie et immunologie. Les résultats seront publiés après la fermeture du marché américain le 6 mai 2024. L'appel mettra à jour les informations concernant les affaires d'Enanta, la recherche et le développement de son pipeline.
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) wird am 6. Mai um 16:30 Uhr ET eine Telefonkonferenz abhalten, um über die Finanzergebnisse für das am 31. März 2024 beendete fiskalische zweite Quartal zu diskutieren. Enanta ist ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf kleine Moleküle für virologische und immunologische Indikationen spezialisiert. Die Ergebnisse werden nach dem Schließen des US-Marktes am 6. Mai 2024 berichtet. Das Gespräch wird ein Update über Enantas Geschäft, Forschung und Entwicklungs-Pipeline bieten.
Positive
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) to report financial results for its fiscal second quarter ended March 31, 2024.
Conference call scheduled for May 6 at 4:30 p.m. ET to discuss results and provide business update.
Enanta focuses on small molecule drugs for virology and immunology indications.
Negative
None.
WATERTOWN, Mass.--(BUSINESS WIRE)--
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2024, after the U.S. market closes on May 6, 2024. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its research and development pipeline.
Conference Call and Webcast Information
The live webcast can be accessed under "Events & Presentations" in the investors section of Enanta’s website. To join by phone, participants can register for the call here. It is recommended that participants register a day in advance or at a minimum of 15 minutes before the call. Once registered, participants will receive an email with the dial-in information. The archived webcast will be available on Enanta’s website for approximately 30 days following the event.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for virology and immunology indications. Enanta’s research and development programs are currently focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU) and the company has previously advanced clinical-stage compounds for SARS-CoV-2 (COVID-19) and chronic hepatitis B virus (HBV) infection.
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis C virus infection (HCV) and is sold by AbbVie in numerous countries under the trade names MAVYRET®(U.S.) and MAVIRET®(ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit http://www.enanta.com for more information.
enanta pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis c virus (hcv). these inhibitors include members of the direct acting antiviral (daa) inhibitor classes – protease (partnered with abbvie), ns5a, and nucleotide polymerase – as well as a host-targeted antiviral (hta) inhibitor class targeted against cyclophilin. enanta’s lead protease inhibitor, paritaprevir, is part of abbvie’s recently approved hcv treatment regimen. in addition, enanta has a preclinical program in non-alcoholic steatohepatitis, or nash, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver. enanta pharmaceuticals is a public company with offices in watertown, ma.
